HHLA2 and interstitial lung disease: Furthermore, while currently available immune checkpoint inhibitors are known to have immune-related side effects, including development of ILD [76], our findings of upregulation of HHLA2 expression in UIP ILD samples could indicate a potential therapeutic target of interest for IPF.